Great. Well thanks very much, everyone, for joining us for our next session with Vertex. My name is Dave Risinger. For those of you who don't know me, I cover Diversified Biopharmaceuticals.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

About 52 per cent of employees experience burnout due to poor work-life balance, showed a survey conducted in five states in ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Enliven Therapeutics (ELVN – Research Report). The company’s ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Hold rating on Caribou Biosciences (CRBU – Research Report), with a ...

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $192.43 average price target. The company has a one-year high of $238.00 and a one-year low of ...

Detailed price information for Ascend Wellness Holdings Inc (AAWH) from The Globe and Mail including charting and trades.

It's worth mentioning that the Orum deal comes as Vertex has sued the US Government for failing to cover a fertility support programme for Casgevy, for example freezing and storing eggs.

Google has released four new open-source AI models under the Gemma 3 series, which are tailor-made for deploying on mobile ...

I used 7 prompts to highlight the enhanced features of Claude 3.7 Sonnet, Anthropic's most advanced model to date.

Vertex' portfolio has been steadily expanded with new product launches to cover the majority of CF mutations, and so it has been looking at new therapeutic categories – including T1D ...

Officers, 10% owners, and other insiders have shelled out more than $10 million on each of these four biotech stocks in the ...